NZ599430A - A drug delivery system for the prevention of cerebral vasospasm - Google Patents
A drug delivery system for the prevention of cerebral vasospasmInfo
- Publication number
- NZ599430A NZ599430A NZ599430A NZ59943008A NZ599430A NZ 599430 A NZ599430 A NZ 599430A NZ 599430 A NZ599430 A NZ 599430A NZ 59943008 A NZ59943008 A NZ 59943008A NZ 599430 A NZ599430 A NZ 599430A
- Authority
- NZ
- New Zealand
- Prior art keywords
- vasospasm
- risk
- therapeutic agent
- pharmaceutical composition
- cerebral artery
- Prior art date
Links
- 208000001286 intracranial vasospasm Diseases 0.000 title abstract 2
- 238000012377 drug delivery Methods 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 5
- 229940124597 therapeutic agent Drugs 0.000 abstract 4
- 206010047163 Vasospasm Diseases 0.000 abstract 3
- 210000001627 cerebral artery Anatomy 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 102000002045 Endothelin Human genes 0.000 abstract 2
- 108050009340 Endothelin Proteins 0.000 abstract 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 2
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- 239000011859 microparticle Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 210000002330 subarachnoid space Anatomy 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 230000001839 systemic circulation Effects 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94312407P | 2007-06-11 | 2007-06-11 | |
| US97690207P | 2007-10-29 | 2007-10-29 | |
| NZ581836A NZ581836A (en) | 2007-06-11 | 2008-06-11 | A drug delivery system for the prevention of cerebral vasospasm |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ599430A true NZ599430A (en) | 2014-03-28 |
Family
ID=40096090
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ599430A NZ599430A (en) | 2007-06-11 | 2008-06-11 | A drug delivery system for the prevention of cerebral vasospasm |
| NZ581836A NZ581836A (en) | 2007-06-11 | 2008-06-11 | A drug delivery system for the prevention of cerebral vasospasm |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ581836A NZ581836A (en) | 2007-06-11 | 2008-06-11 | A drug delivery system for the prevention of cerebral vasospasm |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8303974B2 (enExample) |
| EP (1) | EP2164497B1 (enExample) |
| JP (1) | JP5576790B2 (enExample) |
| KR (3) | KR101554258B1 (enExample) |
| CN (3) | CN105055300A (enExample) |
| AU (1) | AU2008261668C1 (enExample) |
| CA (1) | CA2690600C (enExample) |
| IL (1) | IL202647A (enExample) |
| NZ (2) | NZ599430A (enExample) |
| WO (1) | WO2008154585A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10092524B2 (en) | 2008-06-11 | 2018-10-09 | Edge Therapeutics, Inc. | Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage |
| CN105055300A (zh) * | 2007-06-11 | 2015-11-18 | R·骆克·麦克唐纳 | 用于预防脑血管痉挛的药物递送系统 |
| EP2308478A1 (en) | 2009-10-06 | 2011-04-13 | Abbott GmbH & Co. KG | Delivery system for sustained release of a calcium-channel blocking agent |
| CN106913874A (zh) * | 2010-02-22 | 2017-07-04 | 优势医疗公司 | 治疗脑的出血性病状的方法和组合物 |
| US8658676B2 (en) * | 2010-10-12 | 2014-02-25 | The Medicines Company | Clevidipine emulsion formulations containing antimicrobial agents |
| WO2012051116A1 (en) | 2010-10-12 | 2012-04-19 | The Medicines Company | Clevidipine emulsion formulations containing antimicrobial agents |
| EP2672983B1 (en) | 2011-02-11 | 2017-04-19 | Edge Therapeutics, Inc. | Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage |
| WO2012138854A1 (en) * | 2011-04-05 | 2012-10-11 | Edge Therapeutics | Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow |
| CN102416013A (zh) * | 2011-12-30 | 2012-04-18 | 湖南九典制药有限公司 | 西尼地平的新用途 |
| US9399019B2 (en) * | 2012-05-09 | 2016-07-26 | Evonik Corporation | Polymorph compositions, methods of making, and uses thereof |
| WO2014165023A1 (en) | 2013-03-12 | 2014-10-09 | Carnegie Mellon University | Coated vaso-occclusive device for treatment of aneurysms |
| CN103211812A (zh) * | 2013-04-02 | 2013-07-24 | 苏州大学附属第一医院 | Skf96365在治疗蛛网膜下腔出血后发生的脑血管痉挛的应用 |
| US10403395B2 (en) * | 2013-10-14 | 2019-09-03 | SecondOpinionExpert, Inc. | Method and apparatus for generating objective medical second opinion |
| WO2016122791A1 (en) * | 2015-01-30 | 2016-08-04 | The Regents Of The University Of California | Spinal subpial gene delivery system |
| US20160346224A1 (en) * | 2015-05-29 | 2016-12-01 | Edge Therapeutics, Inc. | Compositions and methods for reducing visual loss |
| MX2018001507A (es) | 2015-08-03 | 2018-09-18 | Enb Therapeutics Llc | Composiciones y metodos para tratar cánceres asociados con la activacion del etbr. |
| CA3069159A1 (en) | 2017-07-11 | 2019-01-17 | Sustained Nano Systems Llc | Hypercompressed pharmaceutical formulations |
| CN111886010A (zh) | 2018-01-12 | 2020-11-03 | Enb治疗公司 | 用于治疗与etbr激活相关的癌症的氘化化合物、组合物和方法 |
| US20200163947A1 (en) * | 2018-11-02 | 2020-05-28 | Nortic Holdings Inc. | Methods of treatment using nimodipine parenteral formulations |
| US20200315547A1 (en) * | 2019-04-02 | 2020-10-08 | Tencent America LLC | Vertebral artery dissection risk evaluation method, computer device, and storage medium |
| US11103142B2 (en) | 2019-04-02 | 2021-08-31 | Tencent America LLC | System and method for predicting vertebral artery dissection |
| JP7716076B2 (ja) * | 2021-02-04 | 2025-07-31 | 学校法人産業医科大学 | 血管内穿孔によるくも膜下出血モデルの血腫を可視化する方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| JPH09507487A (ja) | 1994-01-05 | 1997-07-29 | アーキュール，インコーポレーテッド | 選ばれた性質を有するアミンイミドおよびオキサゾロンをベースとした分子の系統的モジュール製造 |
| US5712171A (en) | 1995-01-20 | 1998-01-27 | Arqule, Inc. | Method of generating a plurality of chemical compounds in a spatially arranged array |
| JP2909418B2 (ja) * | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5977163A (en) | 1996-03-12 | 1999-11-02 | Pg-Txl Company, L. P. | Water soluble paclitaxel prodrugs |
| WO1999002139A1 (en) | 1997-07-10 | 1999-01-21 | Keith Baker | Methods for universally distributing therapeutic agents to the brain |
| US6284283B1 (en) * | 1999-10-21 | 2001-09-04 | Alkermes Controlled Therapeutics, Inc. | Method of producing sub-micron particles of biologically active agents and uses thereof |
| JP2002003406A (ja) * | 2000-06-21 | 2002-01-09 | Sankyo Co Ltd | 脳血管攣縮予防製剤 |
| US20030032676A1 (en) * | 2001-08-09 | 2003-02-13 | Kimelberg Harold K. | Drugs for treatment of cerebral injury and methods of use thereof |
| US20040224030A1 (en) * | 2003-05-06 | 2004-11-11 | Shastri Venkatram R. | Microsphere delivery systems |
| AU2004259209A1 (en) * | 2003-07-23 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
| CN1480128A (zh) * | 2003-08-06 | 2004-03-10 | 北京扬新科技有限公司 | 一种透明、隐形的外用药物制剂 |
| US20050069591A1 (en) * | 2003-09-30 | 2005-03-31 | Howard Bernstein | Injectable, oral, or topical sustained release pharmaceutical formulations |
| US20060205733A1 (en) | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| US7829527B2 (en) * | 2005-02-02 | 2010-11-09 | University Of Vermont And State Agricultural College | Emergence of a R-type Ca2+ channel (Cav 2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage |
| US20060217340A1 (en) | 2005-03-23 | 2006-09-28 | University Of Vermont And State Agricultural College | Methods and products for treating hypertension by modulation of TRPC3 channel activity |
| CN105055300A (zh) * | 2007-06-11 | 2015-11-18 | R·骆克·麦克唐纳 | 用于预防脑血管痉挛的药物递送系统 |
-
2008
- 2008-06-11 CN CN201510300314.8A patent/CN105055300A/zh active Pending
- 2008-06-11 KR KR1020157012919A patent/KR101554258B1/ko not_active Expired - Fee Related
- 2008-06-11 NZ NZ599430A patent/NZ599430A/en not_active IP Right Cessation
- 2008-06-11 AU AU2008261668A patent/AU2008261668C1/en not_active Ceased
- 2008-06-11 WO PCT/US2008/066576 patent/WO2008154585A1/en not_active Ceased
- 2008-06-11 US US12/137,320 patent/US8303974B2/en not_active Expired - Fee Related
- 2008-06-11 CN CN201610281218.8A patent/CN105963242A/zh active Pending
- 2008-06-11 CA CA2690600A patent/CA2690600C/en not_active Expired - Fee Related
- 2008-06-11 KR KR1020107000554A patent/KR101554250B1/ko not_active Expired - Fee Related
- 2008-06-11 JP JP2010512324A patent/JP5576790B2/ja not_active Expired - Fee Related
- 2008-06-11 EP EP08770723.8A patent/EP2164497B1/en not_active Not-in-force
- 2008-06-11 CN CN200880101555.8A patent/CN101873858B/zh not_active Expired - Fee Related
- 2008-06-11 KR KR1020147036026A patent/KR101607244B1/ko not_active Expired - Fee Related
- 2008-06-11 NZ NZ581836A patent/NZ581836A/en not_active IP Right Cessation
-
2009
- 2009-12-10 IL IL202647A patent/IL202647A/en active IP Right Grant
-
2012
- 2012-07-22 US US13/555,182 patent/US20130022660A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101873858A (zh) | 2010-10-27 |
| NZ581836A (en) | 2012-07-27 |
| CN105963242A (zh) | 2016-09-28 |
| KR20100055385A (ko) | 2010-05-26 |
| AU2008261668B2 (en) | 2013-08-29 |
| IL202647A0 (en) | 2010-06-30 |
| AU2008261668C1 (en) | 2014-01-16 |
| AU2008261668A1 (en) | 2008-12-18 |
| US20080305147A1 (en) | 2008-12-11 |
| CN101873858B (zh) | 2016-05-25 |
| EP2164497A4 (en) | 2013-05-29 |
| KR101554250B1 (ko) | 2015-09-18 |
| CA2690600C (en) | 2016-10-11 |
| JP2010529205A (ja) | 2010-08-26 |
| IL202647A (en) | 2015-02-26 |
| US20130022660A1 (en) | 2013-01-24 |
| WO2008154585A1 (en) | 2008-12-18 |
| CA2690600A1 (en) | 2008-12-18 |
| EP2164497A1 (en) | 2010-03-24 |
| KR101554258B1 (ko) | 2015-09-18 |
| CN105055300A (zh) | 2015-11-18 |
| KR20150015514A (ko) | 2015-02-10 |
| KR101607244B1 (ko) | 2016-03-30 |
| KR20150061031A (ko) | 2015-06-03 |
| EP2164497B1 (en) | 2018-08-15 |
| JP5576790B2 (ja) | 2014-08-20 |
| US8303974B2 (en) | 2012-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10172809B2 (en) | Topical regional neuro-affective therapy in mammals with cannabinoids | |
| US10828266B2 (en) | Topical regional neuro-affective therapy with caryophyllene | |
| IL172082A0 (en) | Foamable pharmaceutical compositions and methods for treating a disorder | |
| Brodie et al. | Zonisamide: its pharmacology, efficacy and safety in clinical trials | |
| CA3108214A1 (en) | Extended release formulations of cannabinoids | |
| NZ604029A (en) | Methods of treating bladder cancer | |
| GB0814302D0 (en) | Compounds and methods | |
| DE602004024963D1 (de) | Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer | |
| WO2010011609A3 (en) | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | |
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| MX2014001088A (es) | Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas. | |
| NZ595127A (en) | Stable pharmaceutical composition for atherosclerosis | |
| MY157186A (en) | Drug delivery system for administration of poorly water soluble pharmaceutically active substances | |
| WO2008116161A3 (en) | Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states | |
| MXPA05004780A (es) | Metodos y composiciones que usan farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de canceres y otros padecimientos. | |
| HRP20240812T1 (hr) | Oblici doziranja i terapijska primjena l-4-klorokinurenina | |
| JP2016505050A5 (enExample) | ||
| PH12022552358A1 (en) | Oligosaccharide formulations of kappa opioid receptor agonists | |
| TW200509985A (en) | Drug delivery system for sub-Tenon administration of fine particles | |
| PE20230830A1 (es) | Formulaciones farmaceuticas de acetato de abiraterona y niraparib | |
| IN2015DN04172A (enExample) | ||
| RU2010154623A (ru) | Производные 1-аминоалкилциклогексана для лечения расстройств сна | |
| US20130116244A1 (en) | Pharmaceutical powder compositions | |
| Mason | Remifentanil | |
| Fliser | Olmesartan Medoxomil: A Viewpoint by Danilo Fliser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Error or correction |
Free format text: THE MISSING INVENTOR HAS BEEN ADDED (2435562, R. LOCH MACDONALD, 30 BOND STREET, TORONTO, ON, M5B1W8, CA; 2435563, BRIAN LEUTHNER, 42 OVERHILL ROAD, SUMMIT, NEW JERSEY 07901, US) Effective date: 20140226 Free format text: THE FILED DATE HAS BEEN CORRECTED TO 11/06/2008; THE PATENT COMPLETE SPECIFICATION DATE HAS BEEN CORRECTED TO 11/06/2008 Effective date: 20140226 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 JUN 2015 BY CPA GLOBAL Effective date: 20140919 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUN 2016 BY CPA GLOBAL Effective date: 20150502 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUN 2017 BY CPA GLOBAL Effective date: 20160429 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUN 2018 BY CPA GLOBAL Effective date: 20170505 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUN 2019 BY COMPUTER PACKAGES INC Effective date: 20180518 |
|
| LAPS | Patent lapsed |